Kezar Life Sciences Stock Price, News & Analysis

Kezar (Nasdaq: KZR) announced presentations of Phase 2 PORTOLA data in autoimmune hepatitis (AIH) at AASLD The Liver Meeting® 2025 (Nov 7-11, Washington, DC) and Phase 2b PALIZADE data in lupus nephritis at ASN Kidney Week (Nov 5-9, Houston, TX).

Key PORTOLA findings (oral Nov 10, 2025): 36% of steroid-dependent AIH patients on zetomipzomib reached biochemical remission and tapered steroids to ≤5 mg/day versus 0% on placebo; no responders flared during treatment; zetomipzomib was generally well tolerated with mainly mild–moderate injection site reactions. PALIZADE highlights (oral Nov 7, 2025): zetomipzomib 60 mg produced 42% of patients with UPCR ≤0.5 at Week 25 vs 21% placebo and a 64% reduction in SLEDAI-2K from baseline at Week 25.

Kezar Life Sciences (Nasdaq: KZR) announced it is exploring strategic alternatives and retained TD Cowen to support the review while implementing a restructuring and workforce reduction. The FDA canceled a planned Type C meeting about a potential registrational zetomipzomib study in autoimmune hepatitis (AIH) and requested a stand-alone hepatic impairment pharmacokinetic study that would delay AIH trials by ~2 years. The FDA also requires 48-hour in‑unit monitoring for future zetomipzomib trials. Kezar reported ~$90.2M in cash, cash equivalents and marketable securities as of September 30, 2025. Final PORTOLA data will be presented on November 10, 2025 at The Liver Meeting.

Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotech company focused on immune-mediated disease therapeutics, has announced its participation in two major investor conferences in September 2025.

CEO and Co-founder Chris Kirk will attend the 2025 Wells Fargo Healthcare Conference in Boston on September 5 for a fireside chat, and the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8 for a pre-recorded presentation. The Wells Fargo conference presentation will be available via webcast on the company's website and archived for 90 days.

Kezar Life Sciences (Nasdaq: KZR) reported key developments in Q2 2025, highlighting progress with its lead drug candidate zetomipzomib. The FDA removed the partial clinical hold on the PORTOLA Phase 2a trial for autoimmune hepatitis (AIH), where the drug showed promising results with 36% of treated patients achieving complete biochemical response versus 0% in placebo group.

The company's financial position shows $100.8 million in cash and equivalents as of June 30, 2025, down from $132.2 million at end-2024. Q2 2025 net loss improved to $13.7 million ($1.87 per share) compared to $21.5 million in Q2 2024, with reduced R&D expenses of $9.6 million and G&A expenses of $5.0 million.

Kezar has submitted a Type C meeting request with the FDA for Q4 2025 to discuss zetomipzomib's development plan in AIH, and the PORTOLA data has been selected for oral presentation at The Liver Meeting® 2025.

Kezar Life Sciences (Nasdaq: KZR) announced that the FDA has lifted the partial clinical hold on its completed PORTOLA Phase 2a trial of zetomipzomib for autoimmune hepatitis (AIH). The decision follows the FDA's review of a comprehensive safety assessment of the zetomipzomib program.

While development in lupus nephritis (LN) remains suspended, Kezar has received recommendations from the Independent Data Monitoring Committee (IDMC) regarding future LN clinical trials. The company plans to request the FDA lift the clinical hold for zetomipzomib in LN based on these recommendations and internal safety data analysis.

Kezar Life Sciences (NASDAQ: KZR), a clinical-stage biotech company focused on developing novel small molecule therapeutics for immune-mediated diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO and Co-founder Chris Kirk will engage in a fireside chat on June 4, 2025, at 2:35 pm ET in New York. Interested parties can access the webcast through the "Events & Presentations" section of Kezar's website, with the recording remaining available for 90 days post-event.

Kezar Life Sciences (KZR) reported its Q1 2025 financial results and provided updates on its clinical trials. The company announced positive topline data from the PORTOLA Phase 2a trial evaluating zetomipzomib in autoimmune hepatitis (AIH) patients. In the trial, 36% of zetomipzomib-treated patients achieved complete biochemical response with significant steroid reduction, compared to 0% in the placebo group. The median response duration was 27.6 weeks. The company ended Q1 2025 with $114.4 million in cash and equivalents, down from $132.2 million in Q4 2024. Net loss for Q1 2025 was $16.6 million ($2.27 per share), improved from $21.7 million ($2.98 per share) in Q1 2024. R&D expenses decreased to $12.2 million from $17.2 million year-over-year. The company terminated its PALIZADE Phase 2b trial for lupus nephritis following an FDA clinical hold in October 2024.

Kezar Life Sciences (KZR) announced positive topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for autoimmune hepatitis (AIH) treatment. In the trial's key findings, 36% of zetomipzomib-treated patients achieved complete biochemical response with significant steroid reduction, compared to 0% in the placebo group.

The study demonstrated that in the intention-to-treat population, 31% of zetomipzomib patients achieved complete response and steroid taper, versus one placebo patient. Notably, the median response duration was 27.6 weeks, with no disease flares reported in responding patients.

Financial highlights as of December 31, 2024:

• Cash position: $132.2 million
• R&D expenses decreased to $65.7 million from $85.7 million in 2023
• G&A expenses reduced to $23.4 million from $26.5 million in 2023
• Net loss: $83.7 million ($11.49 per share)

Kezar Life Sciences (Nasdaq: KZR) has announced an upcoming presentation of topline results from their PORTOLA Phase 2a trial evaluating zetomipzomib for treating autoimmune hepatitis (AIH). The presentation is scheduled for March 25, 2025, at 8:00 a.m. ET.

The PORTOLA trial is a placebo-controlled, randomized, double-blind Phase 2a clinical trial assessing the efficacy and safety of zetomipzomib in AIH patients. The event will feature presentations from key investigators including Dr. Craig Lammert from Indiana University School of Medicine and Dr. Gideon Hirschfield from Toronto General Hospital, followed by a Q&A session.

The presentation will be accessible via live audio webcast with slides, and a replay will be available for 90 days afterward on the company's website.